Market Overview

Applied Genetic Slumps Despite Encouraging Data For Gene Therapy To Treat Rare Inherited Visual Disorder

Share:
Applied Genetic Slumps Despite Encouraging Data For Gene Therapy To Treat Rare Inherited Visual Disorder

Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC) are tumbling Thursday despite the company reporting encouraging results from an Phase 1/2 study.

The Cambridge, Massachusetts-based company released interim results from the dose-escalation cohorts of its ongoing Phase 1/2 clinical studies that evaluated its AAV-based gene therapy in patients with achromatopsia resulting from mutations in the ACHM CNGB3 or ACHM CNGA3 genes, which showed encouraging signs of biologic activity and a favorable safety profile, with no dose-limiting inflammatory responses observed.

Achromatopsia is a condition characterized by total or partial absence of color vision. It has no current treatment options.

"We are further encouraged by many patients' real-world positive anecdotes," the company said.

Related Link: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

The interim data were from 22 patients, 13 in the ACHM CNGB3 trial and 9 in the ACHM CNGA3 trial, Applied Genetic said.

Applied Genetic said it expects to report data from the additional dose groups, age groups and time points in the second half of 2020.

The company reported earlier this month positive results for its AAV-based gene therapy in X-linked retinitis pigmentosa, which triggered a 123% rally on Jan. 9.

Applied Genetic shares were slipping 24% to $7.48 at time of publication.

Posted-In: Biotech News Movers Trading Ideas General Best of Benzinga

 

Related Articles (AGTC)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com